#1 Clinical Trials Search in Europe

Drugs Affecting Bone Structure And Mineralization

This article discusses clinical trials investigating the use of drugs that affect bone structure and mineralization in the treatment of breast cancer. These trials aim to evaluate the effectiveness and safety of these medications in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have previously received endocrine therapy. The study focuses on comparing a new drug called Sacituzumab Govitecan with other standard treatments chosen by physicians.

Table of Contents

What Are Drugs Affecting Bone Structure and Mineralization?

Drugs affecting bone structure and mineralization, also known as nitrogen-containing bisphosphonates, are a class of medications used to treat various bone-related conditions[1]. These drugs play a crucial role in maintaining bone health and preventing bone loss. They are classified under the ATC code M05B, which stands for “Drugs Affecting Bone Structure and Mineralization”[1].

How Do These Drugs Work?

Nitrogen-containing bisphosphonates work by slowing down the process of bone breakdown in the body. They do this by targeting cells called osteoclasts, which are responsible for breaking down old bone tissue. By inhibiting the activity of osteoclasts, these drugs help to maintain bone density and strength[1].

Medical Conditions Treated

While the primary focus of the provided information is on breast cancer treatment, drugs affecting bone structure and mineralization are used to treat various conditions related to bone health. These may include:

  • Osteoporosis: A condition where bones become weak and fragile
  • Paget’s disease of bone: A disorder that causes bones to grow larger and weaker than normal
  • Bone metastases: Cancer that has spread to the bones from other parts of the body
  • Multiple myeloma: A type of blood cancer that affects bone marrow

In the context of breast cancer, these drugs may be used to help prevent or manage bone-related complications that can occur due to the cancer itself or as a side effect of cancer treatments[1].

How Are These Drugs Administered?

According to the information provided, these drugs are typically administered through intravenous use[1]. This means they are given directly into a vein, usually as an infusion in a hospital or clinic setting. Intravenous administration allows the medication to enter the bloodstream quickly and reach the bones effectively.

Duration of Treatment

The maximum treatment period mentioned in the data is 12 months[1]. However, it’s important to note that the actual duration of treatment can vary depending on the specific condition being treated, the patient’s response to the medication, and other individual factors. Your healthcare provider will determine the most appropriate treatment duration for your specific situation.

Important Considerations

When taking drugs affecting bone structure and mineralization, there are several important points to keep in mind:

  1. Regular monitoring: Your doctor will likely schedule regular check-ups to monitor your response to the treatment and any potential side effects.
  2. Calcium and vitamin D: These medications often work best when combined with adequate calcium and vitamin D intake. Your doctor may recommend supplements.
  3. Dental health: It’s important to maintain good oral hygiene and inform your dentist about this medication, as it can rarely cause complications with dental procedures.
  4. Side effects: Like all medications, these drugs can have side effects. Common ones may include flu-like symptoms after the first dose, stomach upset, and muscle or joint pain. Serious side effects are rare but can include osteonecrosis of the jaw or atypical femur fractures.
  5. Pregnancy and breastfeeding: If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor as these medications may not be suitable.

Remember, while this information provides a general overview, it’s crucial to consult with your healthcare provider for personalized advice and information about drugs affecting bone structure and mineralization. They can provide guidance tailored to your specific medical condition and overall health status[1].

Aspect Details
Study Type Randomized, Open-label, Phase 3 Study
Main Drug Sacituzumab Govitecan
Comparison Treatment of Physician’s Choice (TPC)
Patient Population HR+/HER2- Metastatic Breast Cancer patients who have received endocrine therapy
Primary Endpoint Progression-Free Survival (PFS)
Secondary Endpoints Overall Survival (OS), Objective Response Rate (ORR), Quality of Life changes
Bone-related Treatment Drugs affecting bone structure and mineralization (e.g., nitrogen-containing bisphosphonates)
Maximum Treatment Duration 12 months

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to compare the effect of Sacituzumab Govitecan (SG) with the Treatment of Physician's Choice (TPC) on Progression-Free Survival (PFS) in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have received endocrine therapy.
  • Who is eligible to participate in this trial? Eligible participants are adults (18 years or older) with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine therapy. They must have measurable disease, adequate organ function, and be candidates for chemotherapy in the metastatic setting.
  • What are the main drugs being studied in this trial? The main drug being studied is Sacituzumab Govitecan. It is being compared to other treatments chosen by physicians, which may include drugs affecting bone structure and mineralization, such as nitrogen-containing bisphosphonates.
  • How long does the treatment in this trial last? The maximum treatment period mentioned in the trial information is 12 months. However, the actual duration may vary depending on the patient's response to treatment and other factors.
  • What are the key outcomes being measured in this trial? The key outcomes being measured include Progression-Free Survival (PFS), Overall Survival (OS), Objective Response Rate (ORR), and changes in quality of life as measured by the EORTC QLQ-C30 questionnaire.

Ongoing Clinical Trials on Drugs Affecting Bone Structure And Mineralization

  • Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +5

Glossary

  • Hormone Receptor-Positive (HR+): A type of breast cancer that has receptors for either estrogen or progesterone hormones. These cancers may respond to hormone therapy treatments.
  • HER2-Negative: Breast cancer cells that do not have high levels of a protein called HER2 on their surface. This affects the type of treatment that may be most effective.
  • Metastatic Breast Cancer: Breast cancer that has spread beyond the breast to other parts of the body, such as the bones, liver, lungs, or brain.
  • Endocrine Therapy: A type of cancer treatment that adds, blocks, or removes hormones to slow or stop the growth of hormone-sensitive tumors.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Bisphosphonates: A class of drugs that help prevent or slow down bone loss and are sometimes used in cancer treatment, especially when cancer has spread to the bones.

References

  1. http://clinicaltrials.eu/trial/study-comparing-sacituzumab-govitecan-with-other-treatments-for-patients-with-hr-her2-metastatic-breast-cancer-after-endocrine-therapy/